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Abstract
Introduction: Intra-dialytic hypotension (IDH) 
is a common complication during hemodialysis 
(HD) treatment. Previous studies have reported 
that modulating dialysate sodium concentration 
combined or not with modulation of  ultrafiltration 
(UF) rate may reduce the incidence of   IDH. The 
aim of the present study was to evaluate the effect 
of sodium and UF profiles on the occurrence of 
intra-dialytic complications and dialysis quality.
Methods: From a total of 64 patients, we selected 18 
patients  who suffered from recurrent IDH. Every patient 
received ten HD sessions utilizing each of the following 
treatments: (1) Control: constant sodium concentration 
and UF rates. (2) Sodium and UF profiles: a linearly 
decreasing sodium concentration combined with a 
linearly decreasing UF rate. (3) Sodium profile:decreasing 
sodium concentration with constant UF rate. 
Results: Fourteen patients completed the study protocol. 
The incidence of IDH, mean inter-dialytic weight gain 
and the delivered dialysis dose were not different between 
the three treatments. However, symptomatic episodes of 
IDH were more commonand pre-dialysis systolic blood 
pressure was higher during the second and third treatment 
modalities compared to controls. Isolated sodium profile 
was associated with more malaise and less achievement 
of target session duration compared to the other two 
treatments. Isolated sodium profile was associated with 
less achievement of target UF while combined sodium 
and UF profiles were associated with more achievement 
of target UF compared to controls.
Conclusion: Our results indicate that sodium profile with 
or without UF profile does not have a beneficial effect 
on the incidence of IDH, achievement of target session 
duration or the delivered dialysis dose. 
Keywords : Sodium Profile; Ultrafiltration; Intra-dialytic 
Complications
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Introduction 
Hemodialysis (HD) is a worldwide common treatment 
for end-stage renal disease (ESRD). Although generally 
considered a safe procedure, it can have several adverse 
effects [1]. Intra-dialytic hypotension (IDH) is a common 
complication during dialysis and affects 20-33% of 
hemodialysis patients [2]. The pathophysiology of 
hypotension during dialysis is a decrease of circulating 
volume induced by ultrafiltration (UF).  This is facilitated 
by the decline of extracellular osmolarity caused by the 
active removal of solutes, especially sodium. This results 
in transfer of fluids from outside to inside the cells, 
increasing the intracellular volume and lowering the 
extracellular volume [3].
Other complications that can occur during HD include 
cramps, nausea and vomiting, headache and malaise.
Apart from patients’ subjective discontents, these 
complications often require the early discontinuation of 
the dialysis session before prescribed time and/or fluid 
replacement. This can result in chronic volume overload 
and under-dialysis [4].
It has been suggested that modulating dialysate sodium 
concentration combined or not with UF profiling may 
better preserve circulating blood volume, and thus 
decrease the incidence of hypotensive episodes during 
dialysis [5-7].
Sodium profile is mainly applied with a higher dialysate 
sodium concentration during the first part of the dialysis 
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considered statistically significant. Quantitative variables 
of paired data were compared by analysis of variance 
with repeated measures. Percentages of paired data were 
compared by the Cochrane Q test.
Results
Among 18 patients included in the study, only 14 patients 
completed the three different treatment modalities of 
the study. The remaining patients did not complete the 
study protocol because they were transferred to another 
HD center. Clinical and demographic characteristics 
of patients are shown  Table-1. A total of 420 dialysis 
sessions were conducted during this study. Table-2 shows 
the measured parameters of the three treatment modalities.
There was no difference in terms of occurrence of  IDH 
between  the three treatment modalities. However, the 
use of sodium profile as monotherapy or in combination 
with an UF profile was significantly associated with 
an increased frequency of symptomatic IDH compared 
to control treatment. The pre-dialysis systolic blood 
pressure increased significantly during treatment with 
sodium profile alone or in combination with UF profile 
compared to control treatment. Post-dialysis systolic BP 
was significantly lower during sodium profile treatment 
compared to both other treatment modalities. Post-
dialysis diastolic BP was significantly lower during the 
sodium and UF profiles treatment compared to control 
treatment. Inter dialytic weight gain and dry weight were 
not changed during sodium profile treatment, combined 
or not with UF profile. Episodes of malaise were 
significantly more frequent during the use of sodium 
profile compared to control treatment. These episodes 
were also more frequent during sodium profile treatment 
in comparison with sodium and UF profiles treatment. 
The frequency of other intra-dialytic complications was 
similar during the three treatment modalities.
The  achievement of  target UF rate was significantly higher 
during sodium and UF profiles treatment compared to 
control treatment. This rate was significantly lower during 
sodium profile treatment compared to control treatment.
The achievement of session duration was significantly 
decreased during sodium profile treatment compared to 
both other treatment modalities.The delivered dialysis 
dose was similar during the three phases of the study.
Discussion
Intra-dialytic complications, particularly hypotension, 
remain frequent despite continuous improvements in 
dialytic technologies. Dialysis-induced hypovolemia is 
considered the major causal factor. Change in effective 
blood volume depends on the equilibrium between fluid 
moving outside the body by UF and vascular refilling 
from the interstitial space. Sodium profile combined or 
not with UF profile was designed to improve vascular 
refilling and thereby dialysis tolerance. The results of 
our study showed no difference in terms of occurrence of 
IDH between the three treatment modalities. However, 
sodium profile alone or in combination with UF profile 
was significantly associated with more episodes of 
symptomatic IDH. Indeed, episodes of malaise were 
significantly more frequent during the use of sodium 
profile compared to control treatment.
Sodium profile alone has been frequently reported as a 
useful tool to improve dialysis tolerance [8, 9, 14-16]. 
Tang et al reported 62% reduction in the frequency of 
hypotension with the linearly decreasing sodium profile 
in 13 patients [17]. Many authors also evaluated the 
effect of sodium profile combined with UF profile on 
IDH. Using sodium and UF profiles in a linear model, 
Zhou et al and, and more recently Shahgholian et al, have 
demonstrated a significant reduction of IDH compared to 
conventional hemodialysis [2, 18]. A beneficial effect on 
IDH has also been reported with sodium profile combined 
with UF profile using a gradual model [19]. However, 
other authors have shown that the use of a sodium profile 
(combined or not with UF profile) did not improve 
the incidence of IDH. Iselin et al reported no effect on 
the occurrence of hypotension or the preservation of 
blood volume with a linearly decreasing sodium profile 
(sodium concentration from 145 to 133 mmol/L) adapted 
to a linearly decreasing UF profile [20]. A  study by Zhou 
and his colleagues concluded that during a similar model 
of sodium and UF profiles, hypotensive episodes were 
significantly reduced, but sodium profile or UF profile as 
mono-therapy had no beneficial effect on intra-dialytic 
hemodynamics [21].In contrast with our results, several 
studies described no changes in pre-dialysis and post-
dialysis systolic and diastolic blood pressures with the 
use of variable sodium profiles [3, 5, 16, 22].In some 
studies, inter-dialytic weight gain and estimated dry 
weight were not changed with sodium profile (combined 
or not with UF profile) [16, 22, 23], while other studies 
had reported a significant increase in weight gain  [7, 24, 
25]. In this study, we did not evaluate sodium gain with 
the use of sodium profile.
In our study, malaise was significantly more frequent 
with the use of sodium profile in comparison with 
control treatment. The frequency of other intra-dialytic 
complications was similar in the three treatment 
modalities in agreement with previous studies [1, 25].
Al-Hillali et al evaluated the effect of combining sodium 
and UF profiles on intra-dialytic symptoms. The results 
of their study don’t support our findings. They reported 
intra-dialytic symptoms in 29 patients before applying 
the profiles and in only 21 patients after using the profiles 
session, when the blood urea concentration and urea 
removal rates are high. This tends to lessen the inevitable 
decrease of plasma osmolality due to urea removal and 
reduce the resultant shift of fluids from the outside to the 
inside of cells.  A lower dialysate sodium concentration 
during the remainder of the dialysis session avoids 
sodium accumulation [8, 9].
UF profile is usually designed to extract the major part of 
the total UF volume in the first part of the session when 
the patient is over-hydrated, to induce elevation of the 
plasma oncotic pressure and to provide a greater driving 
force for vascular refilling, and thus better blood volume 
preservation [10-12].
A combination of sodium and UF profiles was proposed to 
improve cardiovascular stability by increasing dialysate 
sodium concentration to enhance plasma refilling during 
periods of high UF rate and by decreasing dialysate 
sodium concentration when refilling appears less critical 
during periods of slow UF [12, 13].
Technological advances equipped modern HD machines 
with features that allow varying sodium concentrations in 
the dialysate and UF rates according to linear or stepwise 
models. There is controversy about the safety and efficacy 
of the routine use of these profiles. The aim of the 
present study was to evaluate the effect of sodium profile 
combined or not with UF profile on the occurrence of 
intra-dialytic complications and hemodynamic stability. 
Another goal was to test the hypothesis that using sodium 
profile would improve dialysis efficacy in terms of 
achieving targets such as UF volume, session duration 
and delivered dose of dialysis.
Methods
This  was a prospective study conducted in our dialysis 
unit from July to December 2010. Out of a total of 64 
adult ESRD patients who underwent maintenance HD in 
the center, we selected 18 patients who were prone to 
IDH. These were stable patients who had been maintained 
on thrice-weekly HD for more than one year and who 
suffered from IDH in more than 30% of HD sessions 
over the previous three months. IDH was defined as a 
decrease in systolic blood pressure by more than 30%.
Exclusion criteria were cardiac failure, antihypertensive 
medications, blood transfusion during hemodialysis, 
active bleeding, a poorly functioning arteriovenous fistula 
and excessive food consumption before HD session. All 
patients gave their informed consent to participate in the 
study.
The  target  weight was evaluated and readjusted if 
necessary by the attending nephrologists who were not 
involved in the design or analysis of the study. Dry body 
weight was determined individually based on blood 
pressure (BP), absence of peripheral and/or pulmonary 
oedema and echocardiography data.All treatments were 
performed using FMC 4008S (Fresenius Medical Care 
AG, Bad Homberg, Germany), polysufone low flux 
dialysers and bicarbonate buffered dialysate (sodium 
139 mmol/l, potassium 2 mmol/l, calcium 1.50 mmol/l, 
magnesium 0.5 mmol/l, bicarbonate 29 mmol/l). Blood 
flow rate was individualized from 250 to 320 ml/
min. Dialysate flow rate was 500 ml/min. Dialysate 
temperature was 37°C. During the study, dialyser surface 
area, blood flow rates, anticoagulation during the session 
and the dosage of erythropoietin were maintained 
unchanged.If inter-dialytic weight gain was <1.6% of dry 
weight (corresponding to 1 Kg of weight gain for 60 Kg 
of dry weight) the  dialysis session was excluded from 
data analysis.
Each one of the following treatment modalities was 
applied during ten HD sessions for each patient. First 
modality (control): constant sodium concentration of 
139 mmoL/L with constant UF rate. Second modality 
(sodium and UF profiles): linearly decreasing sodium 
concentration with the initial sodium concentration set at 
147 mmoL/L falling to 131mmol/l at the end of dialysis, 
combined with a linearly decreasing UF rate. Third 
modality (sodium profile): the same model in the second 
modality with constant UF rate. Clinical parameters were 
measured for all sessions.We used the same electronic 
scale (Seca) for measuring weight throughout the 
study. Blood pressure (BP) was measured in the supine 
position 5 min before the session, every 30 minutes 
during the session, at the end of the session just before 
extracorporeal volume infusion and if symptoms of 
hypotension occurred. BP was measured using Fresenius 
BP monitor. Symptomatic hypotension was defined as 
IDH accompanied by hypotensive symptoms such as 
dizziness, frequent yawning or perspiration, or an event 
that required immediate intervention. Delivered HD dose 
was presented by Kt/V according to the ionic dialysance 
method using the on-line clearance monitor (OCM).
The achievement of target UF and session duration 
were represented by a ratio according to the following 
formulae: 
Target UF achieved = (actual UF volume / inter-dialytic 
weight gain) x 100 
Target session duration achieved = (actual session 
duration / planned session duration) x 100
Data was analyzed using the Statistic Package for 
Social Sciences software for Windows (SPSS version 
10.0). Quantitative variables were expressed as mean ± 
standard deviations. Qualitative variables were expressed 
as numbers and percentages. A value of P<0.05 was 
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considered statistically significant. Quantitative variables 
of paired data were compared by analysis of variance 
with repeated measures. Percentages of paired data were 
compared by the Cochrane Q test.
Results
Among 18 patients included in the study, only 14 patients 
completed the three different treatment modalities of 
the study. The remaining patients did not complete the 
study protocol because they were transferred to another 
HD center. Clinical and demographic characteristics 
of patients are shown  Table-1. A total of 420 dialysis 
sessions were conducted during this study. Table-2 shows 
the measured parameters of the three treatment modalities.
There was no difference in terms of occurrence of  IDH 
between  the three treatment modalities. However, the 
use of sodium profile as monotherapy or in combination 
with an UF profile was significantly associated with 
an increased frequency of symptomatic IDH compared 
to control treatment. The pre-dialysis systolic blood 
pressure increased significantly during treatment with 
sodium profile alone or in combination with UF profile 
compared to control treatment. Post-dialysis systolic BP 
was significantly lower during sodium profile treatment 
compared to both other treatment modalities. Post-
dialysis diastolic BP was significantly lower during the 
sodium and UF profiles treatment compared to control 
treatment. Inter dialytic weight gain and dry weight were 
not changed during sodium profile treatment, combined 
or not with UF profile. Episodes of malaise were 
significantly more frequent during the use of sodium 
profile compared to control treatment. These episodes 
were also more frequent during sodium profile treatment 
in comparison with sodium and UF profiles treatment. 
The frequency of other intra-dialytic complications was 
similar during the three treatment modalities.
The  achievement of  target UF rate was significantly higher 
during sodium and UF profiles treatment compared to 
control treatment. This rate was significantly lower during 
sodium profile treatment compared to control treatment.
The achievement of session duration was significantly 
decreased during sodium profile treatment compared to 
both other treatment modalities.The delivered dialysis 
dose was similar during the three phases of the study.
Discussion
Intra-dialytic complications, particularly hypotension, 
remain frequent despite continuous improvements in 
dialytic technologies. Dialysis-induced hypovolemia is 
considered the major causal factor. Change in effective 
blood volume depends on the equilibrium between fluid 
moving outside the body by UF and vascular refilling 
from the interstitial space. Sodium profile combined or 
not with UF profile was designed to improve vascular 
refilling and thereby dialysis tolerance. The results of 
our study showed no difference in terms of occurrence of 
IDH between the three treatment modalities. However, 
sodium profile alone or in combination with UF profile 
was significantly associated with more episodes of 
symptomatic IDH. Indeed, episodes of malaise were 
significantly more frequent during the use of sodium 
profile compared to control treatment.
Sodium profile alone has been frequently reported as a 
useful tool to improve dialysis tolerance [8, 9, 14-16]. 
Tang et al reported 62% reduction in the frequency of 
hypotension with the linearly decreasing sodium profile 
in 13 patients [17]. Many authors also evaluated the 
effect of sodium profile combined with UF profile on 
IDH. Using sodium and UF profiles in a linear model, 
Zhou et al and, and more recently Shahgholian et al, have 
demonstrated a significant reduction of IDH compared to 
conventional hemodialysis [2, 18]. A beneficial effect on 
IDH has also been reported with sodium profile combined 
with UF profile using a gradual model [19]. However, 
other authors have shown that the use of a sodium profile 
(combined or not with UF profile) did not improve 
the incidence of IDH. Iselin et al reported no effect on 
the occurrence of hypotension or the preservation of 
blood volume with a linearly decreasing sodium profile 
(sodium concentration from 145 to 133 mmol/L) adapted 
to a linearly decreasing UF profile [20]. A  study by Zhou 
and his colleagues concluded that during a similar model 
of sodium and UF profiles, hypotensive episodes were 
significantly reduced, but sodium profile or UF profile as 
mono-therapy had no beneficial effect on intra-dialytic 
hemodynamics [21].In contrast with our results, several 
studies described no changes in pre-dialysis and post-
dialysis systolic and diastolic blood pressures with the 
use of variable sodium profiles [3, 5, 16, 22].In some 
studies, inter-dialytic weight gain and estimated dry 
weight were not changed with sodium profile (combined 
or not with UF profile) [16, 22, 23], while other studies 
had reported a significant increase in weight gain  [7, 24, 
25]. In this study, we did not evaluate sodium gain with 
the use of sodium profile.
In our study, malaise was significantly more frequent 
with the use of sodium profile in comparison with 
control treatment. The frequency of other intra-dialytic 
complications was similar in the three treatment 
modalities in agreement with previous studies [1, 25].
Al-Hillali et al evaluated the effect of combining sodium 
and UF profiles on intra-dialytic symptoms. The results 
of their study don’t support our findings. They reported 
intra-dialytic symptoms in 29 patients before applying 
the profiles and in only 21 patients after using the profiles 
session, when the blood urea concentration and urea 
removal rates are high. This tends to lessen the inevitable 
decrease of plasma osmolality due to urea removal and 
reduce the resultant shift of fluids from the outside to the 
inside of cells.  A lower dialysate sodium concentration 
during the remainder of the dialysis session avoids 
sodium accumulation [8, 9].
UF profile is usually designed to extract the major part of 
the total UF volume in the first part of the session when 
the patient is over-hydrated, to induce elevation of the 
plasma oncotic pressure and to provide a greater driving 
force for vascular refilling, and thus better blood volume 
preservation [10-12].
A combination of sodium and UF profiles was proposed to 
improve cardiovascular stability by increasing dialysate 
sodium concentration to enhance plasma refilling during 
periods of high UF rate and by decreasing dialysate 
sodium concentration when refilling appears less critical 
during periods of slow UF [12, 13].
Technological advances equipped modern HD machines 
with features that allow varying sodium concentrations in 
the dialysate and UF rates according to linear or stepwise 
models. There is controversy about the safety and efficacy 
of the routine use of these profiles. The aim of the 
present study was to evaluate the effect of sodium profile 
combined or not with UF profile on the occurrence of 
intra-dialytic complications and hemodynamic stability. 
Another goal was to test the hypothesis that using sodium 
profile would improve dialysis efficacy in terms of 
achieving targets such as UF volume, session duration 
and delivered dose of dialysis.
Methods
This  was a prospective study conducted in our dialysis 
unit from July to December 2010. Out of a total of 64 
adult ESRD patients who underwent maintenance HD in 
the center, we selected 18 patients who were prone to 
IDH. These were stable patients who had been maintained 
on thrice-weekly HD for more than one year and who 
suffered from IDH in more than 30% of HD sessions 
over the previous three months. IDH was defined as a 
decrease in systolic blood pressure by more than 30%.
Exclusion criteria were cardiac failure, antihypertensive 
medications, blood transfusion during hemodialysis, 
active bleeding, a poorly functioning arteriovenous fistula 
and excessive food consumption before HD session. All 
patients gave their informed consent to participate in the 
study.
The  target  weight was evaluated and readjusted if 
necessary by the attending nephrologists who were not 
involved in the design or analysis of the study. Dry body 
weight was determined individually based on blood 
pressure (BP), absence of peripheral and/or pulmonary 
oedema and echocardiography data.All treatments were 
performed using FMC 4008S (Fresenius Medical Care 
AG, Bad Homberg, Germany), polysufone low flux 
dialysers and bicarbonate buffered dialysate (sodium 
139 mmol/l, potassium 2 mmol/l, calcium 1.50 mmol/l, 
magnesium 0.5 mmol/l, bicarbonate 29 mmol/l). Blood 
flow rate was individualized from 250 to 320 ml/
min. Dialysate flow rate was 500 ml/min. Dialysate 
temperature was 37°C. During the study, dialyser surface 
area, blood flow rates, anticoagulation during the session 
and the dosage of erythropoietin were maintained 
unchanged.If inter-dialytic weight gain was <1.6% of dry 
weight (corresponding to 1 Kg of weight gain for 60 Kg 
of dry weight) the  dialysis session was excluded from 
data analysis.
Each one of the following treatment modalities was 
applied during ten HD sessions for each patient. First 
modality (control): constant sodium concentration of 
139 mmoL/L with constant UF rate. Second modality 
(sodium and UF profiles): linearly decreasing sodium 
concentration with the initial sodium concentration set at 
147 mmoL/L falling to 131mmol/l at the end of dialysis, 
combined with a linearly decreasing UF rate. Third 
modality (sodium profile): the same model in the second 
modality with constant UF rate. Clinical parameters were 
measured for all sessions.We used the same electronic 
scale (Seca) for measuring weight throughout the 
study. Blood pressure (BP) was measured in the supine 
position 5 min before the session, every 30 minutes 
during the session, at the end of the session just before 
extracorporeal volume infusion and if symptoms of 
hypotension occurred. BP was measured using Fresenius 
BP monitor. Symptomatic hypotension was defined as 
IDH accompanied by hypotensive symptoms such as 
dizziness, frequent yawning or perspiration, or an event 
that required immediate intervention. Delivered HD dose 
was presented by Kt/V according to the ionic dialysance 
method using the on-line clearance monitor (OCM).
The achievement of target UF and session duration 
were represented by a ratio according to the following 
formulae: 
Target UF achieved = (actual UF volume / inter-dialytic 
weight gain) x 100 
Target session duration achieved = (actual session 
duration / planned session duration) x 100
Data was analyzed using the Statistic Package for 
Social Sciences software for Windows (SPSS version 
10.0). Quantitative variables were expressed as mean ± 
standard deviations. Qualitative variables were expressed 
as numbers and percentages. A value of P<0.05 was 
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(P<0.05) [26]. Song et al demonstrated that a step-down 
sodium profile in 11 patients failed to improve dialysis 
tolerance. When sodium profile was combined with the 
stepwise decreasing UF profile, they obtained a reduction 
of intra-dialytic malaise [15].
Song et al [12] extended their evaluation to the delivery 
of dialysis dose, maintenance of session duration, and UF 
performance. Sodium profile used alone was beneficial 
in these terms. When combined with UF profile, it 
reduced the incidence of dialysis failure (defined as 
discontinuation of the session before 75% of planned 
time). The combination of these profiles was associated 
with less weight gain, better UF performance and a 
post-dialysis weight that was closest to the patient’s 
dry weight. In our study, the achievement of session 
duration decreased significantly when sodium profile 
was used alone. This finding can be explained by the 
higher number of malaise episodes associated with 
earlier discontinuation of the dialysis session during this 
treatment modality. This difference, however, had no 
effect on the delivered dialysis dose.
There are methodological differences in the present study 
as compared with some previous studies.We evaluated 
the effects of sodium and UF profiles not only on the 
incidence of intra-dialytic complication sbut also on 
delivered dialysis dose and UF performance. The patients 
and their attending nephrologists dealing with dry 
weight and UF targets were both blinded to the assigned 
treatments modality. We do understand that there are 
several limitations to the present study. The relatively 
small number of cases might mean that the study is not 
sufficiently powered to detect significant difference in 
some parameters. The estimated values of dry weight 
might not be accurate. Dry weight was estimated 
essentially on the basis of subjective criteria. Inter-
dialytic problems and sodium gain were not evaluated.
Currently, blood volume controlled feedback systems are 
available [27, 28]. These systems directly monitor the 
change in blood volume during HD and maintain stable 
blood volume by adjusting the UF rate and dialysate 
conductivity. These technological developments could 
guarantee better intra-dialytic hemodynamic stability in 
the future.
Conclusion
Our results indicate that sodium profile alone or in 
combination with UF profile is not an efficient approach 
to decrease dialysis-related hypotension. Sodium profile 
also failed to reduce the incidence of other intra-dialytic 
complications or improve the achievement of targeted 
UF and session duration.
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Table 2:  Results of the different parameters measured during the three phases of the study
P1 = P value comparing control treatment versus sodium and UF profiles
P2 = P value comparing control treatment versus isolated sodium profile









P P1 P2 P3
Inter-dialytic weight gain (g) 2095 ± 509 2107 ± 470 2209 ± 476 0.098 - - -
Pre-dialysis systolic BP (mm Hg) 134 ± 13 139 ± 16 138 ± 14 0.003 0.004 0.041 1
Post-dialysis systolic BP (mm Hg) 128 ±  16 128 ± 17 124 ±13 0.046 0.93 0.029 0.035
Pre-dialysis diastolic BP (mm Hg) 66 ± 12 67 ± 12 64 ± 12 0.081 - - -
Post-dialysis distolic BP (mm Hg) 65± 10 60 ±19 64 ± 10 0.015 0.024 1 0.056
Hypotension (n, %) 49 (35) 50 (35.7) 49 (35) 0.99 - - -
Symptomatic hypotension (n, %) 9 (6.4) 20 (14.3) 21 (15) 0.049 0.031 0.02 0.866
Asymptomatic hypotension (n, %) 40 (28.6) 30 (21.4) 28 (20) 0.418 - - -
Malaise (n, %) 14 (10) 20 (14.3) 43 (30.7) < 0.001 0.272 < 0.001 0.001
Headache(n, %) 3 (2.1) 3 (2.1) 1 (0.7) 0.559 - - -
Nausea and/or vomiting (n, %) 1 (0.7) 0 1 (0.7) 0.605 - - -
Cramps(n, %) 4 (2.9) 6 (4.3) 9 (6.4) 0.351 - - -
UF (ml) 2147 ± 514 2268 ± 435 2184 ± 434 0.081 - - -
Target UF achieved (n, %) 0.96 ± 0.05 0.99 ± 0.01 0.92 ± 0.08 < 0.001 0.001 <0.001 < 0.001
Delivered dose (Kt/V) 1.25 ± 0.11 1.22 ± 0.09 1.23 ± 0.09 0.075 - - -
Target session duration achieved 0.99± 0.01 0.99 ±0.01 0.95 ± 0.04 <0.001 1 <0.001 <0.001
Dry weight (kgs) 62.14 ±7.5 61.96± 7.5 62.02 ± 7.3 0.848 - - -
Variable Summary
Age in years (mean ± SD) 45.2  ± 11.4
Females (number, %) 7 (50%)
Duration on HD in months (mean ± SD) 35.3 ± 15.9
VascularAccess (% arteriovenous fistula) 14 (100)
Dialysis time per week (% twelve hours) 100
Etiology of ESRD:  
   Diabetes, n 10
   Hypertension nephropathy, n 1
   Unknown, n 3
Table 1: Clinical and demographic characteristics of studied patients (n=14)
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(P<0.05) [26]. Song et al demonstrated that a step-down 
sodium profile in 11 patients failed to improve dialysis 
tolerance. When sodium profile was combined with the 
stepwise decreasing UF profile, they obtained a reduction 
of intra-dialytic malaise [15].
Song et al [12] extended their evaluation to the delivery 
of dialysis dose, maintenance of session duration, and UF 
performance. Sodium profile used alone was beneficial 
in these terms. When combined with UF profile, it 
reduced the incidence of dialysis failure (defined as 
discontinuation of the session before 75% of planned 
time). The combination of these profiles was associated 
with less weight gain, better UF performance and a 
post-dialysis weight that was closest to the patient’s 
dry weight. In our study, the achievement of session 
duration decreased significantly when sodium profile 
was used alone. This finding can be explained by the 
higher number of malaise episodes associated with 
earlier discontinuation of the dialysis session during this 
treatment modality. This difference, however, had no 
effect on the delivered dialysis dose.
There are methodological differences in the present study 
as compared with some previous studies.We evaluated 
the effects of sodium and UF profiles not only on the 
incidence of intra-dialytic complication sbut also on 
delivered dialysis dose and UF performance. The patients 
and their attending nephrologists dealing with dry 
weight and UF targets were both blinded to the assigned 
treatments modality. We do understand that there are 
several limitations to the present study. The relatively 
small number of cases might mean that the study is not 
sufficiently powered to detect significant difference in 
some parameters. The estimated values of dry weight 
might not be accurate. Dry weight was estimated 
essentially on the basis of subjective criteria. Inter-
dialytic problems and sodium gain were not evaluated.
Currently, blood volume controlled feedback systems are 
available [27, 28]. These systems directly monitor the 
change in blood volume during HD and maintain stable 
blood volume by adjusting the UF rate and dialysate 
conductivity. These technological developments could 
guarantee better intra-dialytic hemodynamic stability in 
the future.
Conclusion
Our results indicate that sodium profile alone or in 
combination with UF profile is not an efficient approach 
to decrease dialysis-related hypotension. Sodium profile 
also failed to reduce the incidence of other intra-dialytic 
complications or improve the achievement of targeted 
UF and session duration.
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